Loading...
Back to narrative

BTMD: Share Repurchases Will Support Future Upside In This Bullish Outlook

Digital Health Expansion Will Elevate Preventative Care Despite Regulatory Hurdles

BTMD logo
BTMD
AnalystHighTarget
Not Invested
Published 19 May 2025

Update shared on 13 Dec 2025

n/a
n/a
AnalystHighTarget's Fair Value
n/a
Loading
1Y
-57.6%
7D
5.9%

Analysts have modestly raised their price target on biote to reflect stronger expected revenue growth and a higher future earnings multiple, partially offset by more conservative margin and discount rate assumptions.

What's in the News

  • biote Corp. reiterated its 2025 earnings guidance, expecting revenue above $190 million, signaling management confidence in sustained growth (company guidance).
  • Under the January 25, 2024 share repurchase program, the company has completed buybacks totaling 2,008,731 shares, representing 6.11% of shares outstanding for $8.82 million as of the latest tranche update (buyback tranche update).
  • In the most recent reported period from July 1, 2025 to September 30, 2025, biote repurchased 1,011,767 shares, or 3.19% of shares outstanding, for $3.32 million under the same buyback plan (buyback tranche update).
  • A separate buyback authorization announced on June 20, 2024 currently shows no shares repurchased to date. This indicates unused capacity that could support future capital returns (buyback tranche update).

Valuation Changes

  • The discount rate has risen slightly, moving from 6.78% to 6.96%, reflecting a modestly higher required return.
  • The revenue growth expectation has increased meaningfully, from roughly 6.49% to 8.14%, indicating stronger anticipated top line expansion.
  • The net profit margin assumption has fallen significantly, from about 4.06% to 1.81%, pointing to more conservative profitability expectations.
  • The future P/E multiple has increased substantially, from approximately 35.9x to 55.8x, implying a higher valuation placed on forward earnings.
  • The fair value estimate remains unchanged at 6.0, suggesting that offsetting changes in growth, margins, and discount rate leave the overall valuation level stable.

Have other thoughts on biote?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

Disclaimer

AnalystHighTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystHighTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystHighTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.